Thanks@newB for the considered reply and a bit of History .....

Thanks@newB for the considered reply and a bit of History ..

Well management should be working extra hard to keep BVF satisfied with their investment decision..

I think you hit the nail on the head a couple of months back that Management arent big on Market Messaging and Gary is poor at responding to emails,,, lets hope he responds to BVF...

June next week ,,, so Managements ability to accrue SH Value will be monitored between here and the Phase II Top Line Data Announcement..

With such a strong offering of treatments in Phase II SNT is chronically undervalued IMHO but without Positive Market Push we cant expect to see the full Value extracted...

I always find it so strange that a Biotech can invest $30m $50m over 4 years on Phase I and II Trialing but not understand that the data's value is what provides a return to the SH that actually not only paid for the Trials but Managements Wages... with no income BIO's Management team are paid solely from Investor Funds.... then they ignore SH and don't push the boat out to try and maximise SH returns generated by the Data??

RAC was a text book case in how to maximise a return from every scrap of positivity and data.... the climb from 9c to $4 was a work of class..NZT